Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 5205-5214

  Vilmar, Adam Christian ^a   Santoni Rugiu, Eric ^b   Srøensen, Jens Benn ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN 3; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUBULIN; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 79961005073     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0658     Document Type: Article

References (26)

1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
2. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
3. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57.
4. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
5. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010;21:1817-24.
6. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009;27:4254-9.
7. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6. (Pubitemid 23315823)
8. Séve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6. (Pubitemid 41060824)
9. Burkhart CA, Kavallaris M, Band HS. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:O1-O9. (Pubitemid 32146550)
10. Séve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7. (Pubitemid 43056983)
11. Séve P, Lai R, Ding K, Winton T, Butts C, Mackey J, et al. Class III betatubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007;13:994-9. (Pubitemid 46340378)
12. Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009;15:1473-80.
13. Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009;64:565-73.
14. Vilmar A, Santoni-Rugiu E, Sorensen JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 2010;46:1554-62.
15. Scagliotti GV, Parikh P, von PJ, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
16. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. (Pubitemid 23073154)
18. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-42. (Pubitemid 24164250)
19. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555-67. (Pubitemid 27006967)
20. Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 2009;65:377-82.
21. Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 2010;5:320-5.
22. Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, et al. Crossvalidation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2011 Apr 6. [Epub ahead of print].
23. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837-42. (Pubitemid 37533256)
24. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005;6:669-77. (Pubitemid 41222757)
25. McCarroll JA, Gan PP, Liu M, Kavallaris M. betaIII-Tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010;70:4995-5003.
26. Lantuejoul S, Salameire D, Salon C, Brambilla E. Pulmonary preneoplasia - sequential molecular carcinogenetic events. Histopathology 2009;54:43-54.